Global Endometriosis Market Size Study by Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis, Others), by Treatment (Pain Medication, Hormone Birth Control, Gonadotropin-releasing Hormone (GnRH) Analogues, Aromatase Inhib

Global Endometriosis Market Size Study by Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis, Others), by Treatment (Pain Medication, Hormone Birth Control, Gonadotropin-releasing Hormone (GnRH) Analogues, Aromatase Inhibitors, Others), by Route of Administration (Oral, Parenteral, Others), by End-Users (Hospitals, Homecare, Speciality Centres, Others), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and Regional Forecasts 2022-2032

The Global Endometriosis Market is valued at approximately USD 1.22 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.0% over the forecast period 2024-2032. Endometriosis is a chronic medical condition where tissue similar to the lining inside the uterus, called the endometrium, grows outside the uterus. This abnormal growth can occur on the ovaries, fallopian tubes, outer surface of the uterus, and other pelvic organs. Endometriosis can cause significant pain, especially during menstrual periods, and may lead to fertility problems. The endometriosis market is undergoing significant transformation, driven by an increasing emphasis on women's health issues and the introduction of innovative treatments designed to alleviate the suffering associated with this condition. The heightened awareness among women worldwide about their condition and the increasing vocalization regarding their health issues are contributing to the market's growth, making it both highly profitable and significant.

The increasing prevalence of endometriosis has led to greater patient awareness and a shift in research and development focus towards improving treatment options. Government investments in healthcare infrastructure are further propelling the demand for drugs and diagnostic equipment for endometriosis treatment. High-priced hormone-based therapeutics dominate the market, with companies offering patient assistance programs to reduce the cost burden on patients. This approach is expected to drive patient adherence and market growth over the forecast period. However, the market faces challenges due to the lack of non-invasive diagnostic tests for endometriosis, which restrains its growth. The fear associated with non-invasive diagnostics procedures also poses a challenge, despite increasing awareness about early detection.

Key regions considered in the study include North America, Europe, Asia Pacific, Latin America, and the Rest of the World. Asia Pacific dominates the market with the presence of numerous generic manufacturers and rising disposable incomes. Asia Pacific countries present significant opportunities for the life sciences industry, with nations like India and South Korea making strides to establish themselves as major biopharmaceutical innovation hubs. The growing demand for curative treatments for life-threatening diseases emphasizes the importance of drug research and development, thereby driving the demand for related diagnostic and treatment solutions. North America holds the fastest market growth share due to its established regulatory framework, high demand for disease-specific treatment, and advanced healthcare infrastructure. Europe follows closely, driven by the presence of globally marketed players and population growth.

Major market players included in this report are:

Pfizer Inc.

Johnson & Johnson Private Limited

Teva Pharmaceutical Industries Ltd.

Sanofi

Merck & Co., Inc.

Boehringer Ingelheim International GmbH

Novartis AG

GlaxoSmithKline plc

Bayer AG

AstraZeneca

Eli Lilly and Company

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Almirall, S.A

Cadila Pharmaceuticals

The detailed segments and sub-segment of the market are explained below:

By Type:

Superficial Peritoneal Lesion

Endometrioma

Deeply Infiltrating Endometriosis

Others

By Treatment:

Pain Medication

Hormone Birth Control

Gonadotropin-releasing Hormone (GnRH) Analogues

Aromatase Inhibitors

Others

By Route of Administration:

Oral

Parenteral

Others

By End Users:

Hospitals

Homecare

Speciality Centres

Others

By Distribution Channel:

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

By Region:

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.